Affimed (NASDAQ: AFMD) last announced on 11 August the release of its quarterly earnings. The BIO posted earnings growth for a fourth quarter ($0.16), missing a forecast of ($0.12) calculated by ($0.04). Zacks published this period. NASDAQ: AFMD at https://www.webull.com/quote/nasdaq-afmd had a 280.35% negative operating loss and a 135.64% positive equity profit. On average, for the current fiscal year, research analysts expect Affimed’s revenues will be -0.47 per share.
Analysis:
Several analyst reviews based on AFMD. Within a research note dated Wednesday, 1 July, Zacks Investment Research was affimed from a buy recommendation to a sell. SVB Leerink raised the Affimed’s price target from $7.00 to $8.00 and on Wednesday 24th June granted the stock an “outperforming” recommendation. Laidlaw re-established the buy recommendation and set a target price of $10.00 for NASDAQ: AFMDstock in Research. Eventually, on Wednesday 15th July, in a Research Note BidaskClub was reduced from the buy to sell ranking. The stock has been recommended by two investment analysts and a buying recommendation has been given by three on the stock of the firm.
The recent shares:
The organization has recently bought and sold share to eternal institutional investors and investment firms. In the second quarter Bank of Montreal will increase its role in Affimed shares by 7.5%. Bank of Montreal Can has an estimated 18,977 portfolio positions in the past trimester of 271,832 shares of the company of the pharmaceutical business for $1,251,000. In the second quarter, Goldman Sachs Group Inc. raised its stake with Affimed shares by 29.4%. Following the purchase of additional 69,342 shares in the fourth quarter, the Goldman Sachs Group, Inc. currently holds 304,899 shares of the $1,407,000 bio pharmaceutical business portfolio.
In the second quarter the Bank of New York Mellon Corp raised its stake in Affimed’s stock by 6.9%. Bank of New York, after buying 11,101 shares in the last year, now owns 172,538 shares on the portfolio of the bio pharmaceutical company worth $796,000. Globeflex Capital L P picked up a new interest in Affimed stock worth approximately $2,759,000 in the second quarter. In the second quarter, California’s PPRS raised its position in Affimed’s equity by 8.4 percent. The Retirement Program of California Public Employees now holds 162,460 shares worth $750,000 of the biopharmaceutical company, after buyer of 12,560 shares.
About NASDAQ: AFMD:
NASDAQ: AFMD, a bio pharmaceutical corporation of the therapeutic stage in the United States, Europe and Germany, is committed to the research and development of cancer immunotherapy.
Her main drug candidate in Phase 2a clinical trial for relapsed CD30 positive Lymphoma and Phase 1b Antistatic Phase 1 anti-PD-1 Keytruda (pembrolizumab) is a natural killer-cell (NK-cell) TandAb treatment of patients suffering from relapsation of Hodgkin lymphoma. If you want to know more stock information like buying on margin definition, you can download a stock trading app to check more. Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.
